静脉溶栓药物治疗急性缺血性卒中的可视化分析

Visual analysis of intravenous thrombolytic drugs for acute ischemic stroke

目的分析静脉溶栓药物治疗急性缺血性卒中的研究现状、热点及发展趋势。方法通过检索Web of Science核心合集数据库,收集静脉溶栓药物治疗急性缺血性卒中的相关研究,利用CiteSpace 6.1.R6软件对文献的作者、国家/地区、机构及关键词进行可视化分析。结果共纳入文献1810篇,发文量呈逐年增长趋势,以美国(556篇)发文量最多,我国发文量排第2位(339篇)但中心度为0。发文量最多的作者为瑞典的Ahmed(32篇),发文量最多的机构为加拿大的卡尔加里大学(80篇)。目前研究的现状和热点主要为新型溶栓药物的应用及疗效探索,前沿和发展趋势为静脉溶栓药物治疗后伴随的神经系统恶化及出血性转化等不良预后。结论静脉溶栓药物治疗急性缺血性卒中的研究热点和前沿主要为第三代静脉组织纤溶酶原激活物,新型静脉溶栓药物的探索及其有效性、安全性是未来研究的热点。我国学者和研究团队可通过开展多中心临床研究来加强与其他国家的合作交流。

OBJECTIVE To analyze the research status,hotspots and trends in the research of intravenous thrombolytic drugs in the treatment of acute ischemic stroke.METHODS The original studies related to intravenous thrombolytic drugs for acute ischemic stroke were collected by searching the Web of Science core database;the authors,countries/regions,institutions and keywords of the literature were visualized and analyzed using CiteSpace 6.1.R6 software.RESULTS A total of 1810 articles were included,and the number of articles published showed an increasing trend year by year,with the United States(556 articles)having the largest number of articles,and China ranking the second(339 articles,with centrality of 0).The most published author was Ahmed of Sweden(32 articles),and the most published institution was the University of Calgary in Canada(80 articles).The current research status and hotspots were mainly the application and therapeutic exploration of new thrombolytic drugs,and the frontier and development trend were the adverse prognosis of neurological deterioration and hemorrhagic transformation accompanied by intravenous thrombolytic drug treatment.CONCLUSIONS The research hotspots and frontier about intravenous thrombolytic drugs for acute ischemic stroke are mainly the third generation of intravenous tissue plasminogen activator,and the exploration of new intravenous thrombolytic drugs and their safety and effectiveness will be the future research hotspots.Chinese scholars and research teams should strengthen cooperation and exchanges with other countries,which can be strengthened by carrying out multi-center clinical trials.